Vascular Disease: Milestone Achieved By Leading Medical Device Company
Vascular Disease: Milestone Achieved By Leading Medical Device Company
InspireMD Announces Groundbreaking Positive Results from C-GUARDIANS U.S. Clinical Trial.
InspireMD, a global leader in the development of innovative medical devices for the treatment of vascular diseases, recently unveiled positive 30-day follow-up results from its ongoing C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23. These promising findings mark a significant milestone not only for the company but also for the medical community at large and patients suffering from vascular diseases.
These exciting developments were shared by Dr. John Laird, the Principal Investigator of the C-GUARDIANS trial and Medical Director at Adventist Heart and Vascular Institute. "The early results from the C-GUARDIANS trial are very encouraging," said Dr. Laird. "The CGuard™ EPS has shown great promise in preventing embolic events in patients undergoing carotid artery stenting procedures. We are eager to continue our investigation and look forward to sharing additional results in the future."
Marvin Slosman, CEO of InspireMD, also expressed his excitement about the results. "These positive early outcomes from the C-GUARDIANS trial underscore the potential of our CGuard™ EPS to make a significant impact in the field of vascular medicine," he said.
While these results are certainly promising, it’s important to remember that they represent only the initial findings from the ongoing C-GUARDIANS trial. The final results, which will include data from all patients enrolled in the study, are expected to provide a more comprehensive understanding of the CGuard™ EPS's safety and efficacy.
This article includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission. This does not affect the price you pay or the quality of the product you receive, but it does help fund our work.
The positive results from the C-GUARDIANS trial thus far are a testament to InspireMD's commitment to innovation and patient care. As we await further updates from this landmark study, one thing is clear: the future of vascular medicine looks brighter with the CGuard™ EPS in the picture.
Disclaimer: The information contained in this article is for informational purposes only and is not intended as health or medical advice. Always consult a physician or other qualified health provider regarding any questions you may have about a medical condition or health objectives.
As an investor it's important to stay updated with major news. Get real-time alerts by creating an account here.